Biostatistics Shared Resource
The primary goal of the Biostatistics Core is to facilitate the peer-reviewed research of the Comprehensive Cancer Center of Wake Forest University members.
We are responsible for collaborating with clinical, cancer control and basic science investigators throughout all phases of cancer-related research projects designed to:
- Reduce the incidence of cancer
- Increase treatment options
- Improve response and survival
- Reduce morbidity
- Manage symptoms
- Improve health-related quality of life
- Move important laboratory discoveries into clinical practice
Services We Provide
To help achieve this goal we provide the following services free of charge:
- Ensure that study designs (for both protocol and grant submissions) are adequate, including development of study hypotheses, explicit specification of primary and secondary outcomes, determination of required sample sizes, appropriate data collection, and assessment of the feasibility of trials based on previous accrual to other similar trials
- Write the statistical sections for all treatment protocols, including plans for interim monitoring of trial results
- Develop randomization schemes for studies (i.e., phase III clinical trials)
- Assist with the development of sample survey instruments
- Develop sampling plans
- Monitor ongoing protocol accrual
- Provide methodologic support to Cancer Center investigators
- Perform interim data analyses
- Perform ad hoc and final analyses
- Collaborate with investigators when interpreting and publishing results
- Collaborate with Cancer Center members in the development and submission of externally funded grants
- Participate in Cancer Center committees responsible for the scientific and administrative direction of the Cancer Center
Areas of Focus
Statisticians ensure that appropriate designs are used, often resulting in more efficient studies (fewer patients required). Programmers ensure that study forms or questionnaires are reasonable, and they develop the programs for screen entry. Statisticians also ensure that the appropriate statistical tests are performed and interpreted properly.
To facilitate these tasks, Ralph D’Agostino, PhD, developed a new plan for dividing responsibilities among the Biostatistics Core to take advantage of the unique strengths of the core members. This plan involves each Biostatistics Core member having particular types of projects that they will work on, thereby creating continuity among collaborations of Cancer Center members and statisticians.
In addition, to assist in protocol development among Cancer Center members, each Cancer Center member is assigned a specific statistician to work with in the development of the design and statistical analyses. In this way, we develop stronger and more consistent collaborative relationships.
Ralph D’Agostino, PhD
- Lightfoot JC, D'Agostino Jr. RB, Hamilton CA,Jordan J, Torti FM, Kock ND,Workman S, Hundley WG. Novel Approach to Early Detection of Doxorubicin Cardiotoxicity by Gadolinium-Enhanced Cardiovascular Magnetic Resonance Imaging in an Experimental Model. Circulation-Cardiovascular Imaging. 2010;3(5): 550-558.
- Pinnix ZK, Miller LD, Wang W, D'Agostino Jr. R, Kute T, Willingham MC, Hatcher H, Torti SV, Sui G, Di X, Torti FM, Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2(43): 43ra56.
- Chaosuwannakit N, D'Agostino Jr. R, Hamilton CA,Lane KS, Ntim WO, Lawrence J,Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic Stiffness Increases Upon Receipt of Anthracycline Chemotherapy. Journal of Clinical Oncology. 2010;28(1): 166-172.
- Akins EJ, Moore ML, Tang SA,Willingham MC, Tooze JA, Dubey P. In situ Vaccination Combined with Androgen Ablation and Regulatory T-Cell Depletion Reduces Castration-Resistant Tumor Burden in Prostate-Specific Pten Knockout Mice. Cancer Research. 2010;70(9): 3473-3482.
- Sukumvanich P, Case LD, Van Zee K,Singletary SE, Paskett ED, Petrek JA,Naftalis E, Naughton MJ. Incidence and Time Course of Bleeding After Long-Term Amenorrhea After Breast Cancer Treatment A Prospective Study. Cancer. 2010;116(13): 3102-3111.
Ralph D’Agostino, PhD